Brooks Laboratories

Small Cap 5.2k Result

₹90.85

-1.85 (-2%)

As on 27 September, 2023 | 17:33 BSE: 533543 NSE: BROOKSISIN: INE650L01011

Brooks Laboratories Performance

Day Range

Low 89
High 94

90.85

52 Week Range

Low 56.95
High 127.58

90.85

Open Price93.95
Previous Close92.7
Volume159187

Start SIP in Brooks Laboratories

Start SIP

Brooks Laboratories Share Price

Over 1 Month -5.36%
Over 3 Month 23.61%
Over 6 Month 24.2%
Over 1 Year -19.79%

Brooks Laboratories Key Statistics

P/E Ratio	-10.4
PEG Ratio	-1.1
Market Cap Cr	239
Price to Book Ratio	3.2
EPS	-3.1
Dividend	0
Relative Strength Index	37.23
Money Flow Index	44.3
MACD Signal	1.92
Average True Range	3.26

Brooks Laboratories Investment Rating

Master Rating:
Brooks Laboratories has an operating revenue of Rs. 61.70 Cr. on a trailing 12-month basis. An annual revenue de-growth of -31% needs improvement, Pre-tax margin of -55% needs improvement, ROE of -28% is poor and needs improvement. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. From an O'Neil Methodology perspective, the stock has an EPS Rank of 26 which is a POOR score indicating inconsistency in earnings, a RS Rating of 43 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 92 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of C is fair but needs to improve. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Brooks Laboratories Financials

Standalone Consolidated

Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios
Quarterly P&L
Annual P&L
Balance Sheet
Cash Flow
Ratios

Indicator	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Oper Rev Qtr Cr	16	13	12	16	15	21
Operating Expenses Qtr Cr	16	13	13	16	19	21
Operating Profit Qtr Cr	0	0	-1	0	-4	0
Depreciation Qtr Cr	0	0	0	0	0	0
Interest Qtr Cr	0	0	0	0	0	0
Tax Qtr Cr	0	0	0	0	0	0
Net Profit Qtr Cr	-1	-1	-2	-1	-5	0

Indicator	Mar 2023	Mar 2022
Total Revenue Annual Cr	56	78
Operating Expenses Annual Cr	61	75
Operating Profit Annual in Cr	-6	2
Depreciation Cr	2	1
Interest Annual Cr	1	1
Tax Annual Cr	0	0
Net Profit Annual Cr	-8	1

Indicator	Mar 2023	Mar 2022
Cash from Operating Activity Annual Cr		3
Cash from Investing Activity Annual Cr		1
Cash from Financing Annual Activity Cr		-4
Net Cash Flow Annual Cr		0

Indicator	Mar 2023	Mar 2022
Total ShareHolders Funds Annual Cr	57	65
Fixed Assets Annual Cr	15	16
Total Non Current Assets Annual Cr	65	66
Total Current Assets Annual Cr	28	37
Total Assets Annual Cr	92	103

Indicator	Mar 2023	Mar 2022
Book Value Per Share Annual Rs	23	26
ROE Annual %	-14	1
ROCE Annual %	-12	2
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	-10	4

Indicator	Jun 2023	Mar 2023	Dec 2022	Sep 2022	Jun 2022	Mar 2022
Oper Rev Qtr Cr	16	13	15	18	17	28
Operating Expenses Qtr Cr	16	13	24	27	26	32
Operating Profit Qtr Cr	0	0	-9	-9	-9	-4
Depreciation Qtr Cr	0	0	2	2	2	2
Interest Qtr Cr	0	0	1	1	1	1
Tax Qtr Cr	0	0	-2	-4	-2	-1
Net Profit Qtr Cr	-4	-4	-9	-5	-9	-4

Indicator	Mar 2023	Mar 2022
Total Revenue Annual Cr	63	92
Operating Expenses Annual Cr	90	105
Operating Profit Annual in Cr	-26	-14
Depreciation Cr	7	7
Interest Annual Cr	2	3
Tax Annual Cr	-7	-5
Net Profit Annual Cr	-21	-16

Indicator	Mar 2023	Mar 2022
Cash from Operating Activity Annual Cr		-37
Cash from Investing Activity Annual Cr		-25
Cash from Financing Annual Activity Cr		64
Net Cash Flow Annual Cr		2

Indicator	Mar 2023	Mar 2022
Total ShareHolders Funds Annual Cr	74	63
Fixed Assets Annual Cr	15	125
Total Non Current Assets Annual Cr	82	135
Total Current Assets Annual Cr	28	61
Total Assets Annual Cr	110	196

Indicator	Mar 2023	Mar 2022
Book Value Per Share Annual Rs	30	54
ROE Annual %	-28	-26
ROCE Annual %	-43	-14
Total Debt to Total Equity Annual	-	-
EBDIT Annual Margin %	-41	-15

Brooks Laboratories Technicals

EMA & SMA

Current Price

₹90.85

-1.85 (-2%)

Bullish Moving Average
___
5

Bearish Moving Average
___
11

EMA SMA

20 Day
₹99.97

50 Day
₹95.28

100 Day
₹89.33

200 Day
₹88.11

20 Day
₹101.79

50 Day
₹96.18

100 Day
₹81.92

200 Day
₹85.89

Brooks Laboratories Resistance and Support

PIVOT

₹94.07

Resistance
First Resistance	₹98.09
Second Resistance	₹103.47
Third Resistance	₹107.49

RSI	37.23
MFI	44.3
MACD Single Line	1.92
MACD	-0.11

Support
First Resistance	₹88.69
Second Resistance	₹84.67
Third Resistance	₹79.29

Brooks Laboratories Delivery and Volume

Period	NSE + BSE Volume Avg	NSE + BSE Delivery Volume Avg	NSE + BSE Delivery Volume %
Day	95,866	9,586,600	100
Week	33,617	3,361,740	100
1 Month	34,124	3,412,433	100
6 Month	72,178	4,760,148	65.95

Brooks Laboratories Result Highlights

Brooks Laboratories Synopsis

NSE-Medical-Generic Drugs

Brooks Laboratories is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 55.54 Cr. and Equity Capital is Rs. 24.70 Cr. for the Year ended 31/03/2023. Brooks Laboratories Ltd. is a Public Limited Listed company incorporated on 23/01/2002 and has its registered office in the State of Himachal Pradesh, India. Company’s Corporate Identification Number(CIN) is L24232HP2002PLC000267 and registration number is 000267.

Market Cap	238
Sales	56
Shares in Float	0.94
No of funds	1
Yield

Book Value	4.07
U/D Vol ratio	1.9
LTDebt / Equity
Alpha	-0.05
Beta	0.62